Stockscreener 앱 받기
6.12
2.17%
0.13
시간 외 거래:
6.20
0.08
+1.31%
전일 마감가:
$5.99
열려 있는:
$5.88
하루 거래량:
769.30K
Relative Volume:
1.19
시가총액:
$580.67M
수익:
-
순이익/손실:
$-65.10M
주가수익비율:
-8.6477
EPS:
-0.7077
순현금흐름:
$-53.50M
1주 성능:
-9.87%
1개월 성능:
-2.55%
6개월 성능:
+207.54%
1년 성능:
+330.99%
1일 변동 폭
$5.88
$6.36
1주일 범위
$5.88
$6.95
52주 변동 폭
$0.97
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
명칭
Zura Bio Ltd
전화
858-247-0520
주소
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
6.12 | 568.34M | 0 | -65.10M | -53.50M | -0.7077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 개시 | Wedbush | Outperform |
| 2024-11-04 | 개시 | Leerink Partners | Outperform |
| 2024-09-05 | 개시 | H.C. Wainwright | Neutral |
| 2024-05-03 | 개시 | Piper Sandler | Overweight |
| 2023-10-10 | 개시 | Ladenburg Thalmann | Buy |
| 2023-08-25 | 개시 | Oppenheimer | Outperform |
| 2023-06-22 | 개시 | Guggenheim | Buy |
| 2023-06-14 | 개시 | Chardan Capital Markets | Buy |
| 2023-05-24 | 개시 | Raymond James | Strong Buy |
모두보기
Zura Bio Ltd 주식(ZURA)의 최신 뉴스
Zura Bio (NASDAQ: ZURA) outlines autoimmune pipeline, Phase 2 timelines - Stock Titan
Zura Bio 10-K: $0.0M Revenue, $(X.XX) EPS on reported net loss - TradingView
2025 financial update released as Zura Bio outlines new corporate developments - Traders Union
Zura Bio (NASDAQ: ZURA) raises cash to fund Phase 2 trials - Stock Titan
Zura says $144M financing can carry autoimmune drug trials into 2028 - Stock Titan
Ajay Nirula Net Worth (2026) - GuruFocus
Boothbay Fund Management LLC Acquires New Shares in Zura Bio Limited $ZURA - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 16.2% in February - MarketBeat
Zura Bio Limited $ZURA Stock Holdings Boosted by Suvretta Capital Management LLC - MarketBeat
ZURA Technical Analysis & Stock Price Forecast - Intellectia AI
Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA - Defense World
Zura Bio’s Tibulizumab: First-in-Class Bispecific Antibody Targeting IL-17 and BAFF for Autoimmune Diseases (HS & SSc) – Pipeline, Trials, and Market Opportunity 2348 - Minichart
Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program - TipRanks
Zura Bio updates corporate presentation, flags tibulizumab Phase 2 readouts, cash and shares - TradingView
Updated investor presentation furnished by Zura Bio (NASDAQ: ZURA) - Stock Titan
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio presents Phase 2 systemic sclerosis trial design By Investing.com - Investing.com Australia
Zura Bio presents Phase 2 systemic sclerosis trial design - Investing.com South Africa
Zura Bio launches Phase 2 TibuSURE trial in systemic sclerosis at Athens congress - Traders Union
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress - Weekly Voice
Director at Zura Bio (ZURA) awarded 37,812 share options - Stock Titan
Major Zura Bio (ZURA) holder acquires 2M shares in registered deal - Stock Titan
Access Industries group lifts Zura Bio (ZURA) stake to 18.2% - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zura Bio heads to Miami for March 10-11 investor conferences - Stock Titan
Zura Bio raises $144 million in public offering of shares By Investing.com - Investing.com South Africa
Zura Bio raises $144 million in public offering of shares - Investing.com India
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - ChartMill
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
Zura Bio prices $125M public offering at $6.25 per share - Investing.com Australia
Zura Bio (ZURA) launches $6.25 share and pre-funded warrant sale - Stock Titan
Zura Bio (NASDAQ: ZURA) seeks roughly $117M from 18.2M-share offering - Stock Titan
Zura Bio Prices Public Offering of 18.2 Million Shares - Intellectia AI
Zura Bio prices $125M public offering at $6.25 per share By Investing.com - Investing.com South Africa
Zura Bio launches public offering of Class A shares By Investing.com - Investing.com India
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - ChartMill
Zura Bio launches public offering of Class A shares - Investing.com Australia
Director Mark Eisner files initial Form 3 for Zura Bio Ltd (ZURA) - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - Stock Titan
Zura Bio adds two immunology executives to board By Investing.com - Investing.com India
Zura Bio adds two immunology executives to board - Investing.com
Zura Bio (ZURA) appoints Mark Eisner and Ajay Nirula to its board - Stock Titan
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors - ChartMill
Risk Recap: What makes Zura Bio Limited stock attractive todayMarket Sentiment Report & Community Consensus Picks - baoquankhu1.vn
What risks investors should watch in Zura Bio Limited stockGDP Growth & Weekly High Momentum Picks - mfd.ru
Great Point discloses 3.8M Zura Bio (ZURA) shares in 13G/A - Stock Titan
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026 - Yahoo Finance
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 27.7% in January - MarketBeat
Why retail investors favor Zura Bio Limited stockWeekly Stock Recap & Daily Momentum Trading Reports - mfd.ru
ZURA PE Ratio & Valuation, Is ZURA Overvalued - Intellectia AI
Zura Bio Ltd (ZURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):